{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:53Z","timestamp":1777420433055,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of ceftriaxone (CRO) 1 g intravenously (IV) daily to higher doses for treating non-central nervous system (CNS) infections in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>PubMed, Embase, Scopus, and Web of Science were used. A search was run from database inception to August 8, 2023 and rerun May 12, 2025. Search terms were CRO, Rocephin, pneumonia, intra-abdominal infections, appendicitis, typhlitis, pyelonephritis, bacteremia, and sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>\n                      Articles included had to compare CRO 1 g IV daily to higher dosing for the outcomes of interest: clinical cure (CC), hospital length of stay (LOS), mortality, and toxicity. Randomized controlled trials (RCTs) or observational studies were included. Studies including pediatric, pregnant, and outpatient administration were excluded. Clinical cure was evaluated using a Mantel-Haenszel random-effects model with Peto odds ratios (pORs), and 95% confidence intervals (CIs) were calculated. Heterogeneity was identified using Cochrane\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Eight studies (5145 patients) were included. No statistically significant difference was found for CC (pOR 0.958; 95% CI [0.525-1.749];\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 60.23;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .888); LOS (Std difference in means, 0.052; 95% CI [\u22120.418, 0.523];\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 96.047;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .828); or mortality (pOR 0.932; 95% CI [0.789-1.100];\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0.000;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .405).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Ceftriaxone dosing ranges from 1 to 2 g IV daily for treating non-CNS infections. Optimal dosing remains controversial, as RCTs have used different doses. This meta-analysis showed no difference between high and low CRO dosing for efficacy and safety. Because infection type and pharmacokinetic factors were not accounted for, findings may not be applicable to certain high-risk infections or situations where CRO pharmacokinetics are altered, such as hypoalbuminemia. Prospective studies can compare regimens and confirm findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ceftriaxone doses greater than 1 g IV daily did not improve CC, LOS, or mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251346777","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T14:03:59Z","timestamp":1753625039000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of High- and Low-Dose Ceftriaxone Regimens: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-2500","authenticated-orcid":false,"given":"Lindsay","family":"Brust-Sisti","sequence":"first","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA"},{"name":"Jersey City Medical Center, Jersey City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwang-Yee","family":"Hu","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA"},{"name":"Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bridgeman","sequence":"additional","affiliation":[{"name":"Robert Wood Johnson Library of the Health Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-6167","authenticated-orcid":false,"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA"},{"name":"Robert Wood Johnson University Hospital Somerset, Somerville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3665-0158","authenticated-orcid":false,"given":"Jimmy","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA"},{"name":"Jersey Shore University Medical Center, Neptune, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Ceftriaxone injection [package insert]. Fresenius Kabi 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221121252"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-015-1345-y"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03425.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1627872"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02189-21"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad102"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200009000-00023"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/11539220-000000000-00000"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02134-18"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4552-8"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03372-y"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00066-20"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/bf01691490"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.3-57.v2"},{"issue":"1","key":"e_1_3_3_18_2","first-page":"26","article-title":"Comparative clinical evaluation of ceftriaxone in treating lower respiratory tract infections","volume":"5","author":"Abbate GF","year":"1986","unstructured":"Abbate GF, Alagia I, Giaquinto E, et al. Comparative clinical evaluation of ceftriaxone in treating lower respiratory tract infections. Chemioterapia. 1986;5(1):26-32.","journal-title":"Chemioterapia"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/08971900241313399"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000194882"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(03)80132-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1590\/s1413-86702004000100006"},{"issue":"10","key":"e_1_3_3_25_2","first-page":"1283","article-title":"[Management of community acquired pneumonia in adults following clinical guidelines at a rural hospital]","volume":"137","author":"Sanhueza ALM","year":"2009","unstructured":"Sanhueza ALM, V\u00e1squez PC, Sep\u00falveda ZF, Barahona CF, Gonz\u00e1lez CR, Sald\u00edas PF. [Management of community acquired pneumonia in adults following clinical guidelines at a rural hospital]. Rev Med Chil. 2009;137(10):1283-1290.","journal-title":"Rev Med Chil"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw035"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad057"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04575-z"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2018-102911"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01663-23"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123656"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.421"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(95)00053-d"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15819"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251346777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251346777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251346777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:10Z","timestamp":1777374850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251346777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10600280251346777"],"URL":"https:\/\/doi.org\/10.1177\/10600280251346777","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]}}}